GenKyoTex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
- After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were reduced by 23% in the 400mg BID group (p<0.01)
- In patients with higher baseline GGT, reduction in GGT levels was even greater with 29% (p<0.01)
- Alkaline phosphatase (ALP) levels were reduced by 17% in the 400mg BID group (p<0.001)
- Genkyotex to hold a conference call and webcast today at 3:00 pm CET / 09:00 am EDT
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX) announced today that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary and secondary interim efficacy endpoints with high statistical significance after only 6 weeks of treatment. The data establish GKT831 as an attractive therapeutic option in a broad PBC population and support its development in multiple fibrotic diseases including NASH and IPF.
More information on :